Centessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 5:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 5:30 p.m. ET. The company focuses on developing new medicines through an asset-centric model, emphasizing specialized teams for diverse therapeutic areas, including oncology, hematology, and immunology. Centessa owns ten asset-centric companies, ranging from discovery to late-stage development, allowing for strategic resource allocation and shared infrastructure.
Details
News Market Reaction – CNTA
The recorded move for CNTA in the trading session of this news was -1.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8, 2021, beginning at 5:30 p.m. Eastern Time.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc aims to bring impactful new medicines to patients by combining the strengths of an asset-centric model with the benefits of scale and diversification typical of larger R&D organizations. The asset-centric model refers to a highly specialized, singular-focused company that is led by a team of well-recognized subject matter experts. Centessa wholly owns ten of these asset-centric companies. The companies’ programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. Centessa’s asset-centric companies are overseen by the Centessa management team, which sets overall strategy and direction, provides leadership and expertise, and manages resource allocation and shared infrastructure. For more information, visit www.centessa.com.
Contacts:
| Investor Contact: | Media Contacts: |
| Jennifer Porcelli, Head of Investor Relations | US |
| Centessa Pharmaceuticals | Dan Budwick, 1AB |
| jennifer.porcelli@centessa.com | dan@1abmedia.com |
| UK/Greater Europe | |
| Mary Clark & Shabnam Bashir, Optimum Strategic Communications | |
| centessa@optimumcomms.com | |
| Switzerland | |
| Marcus Veith, VEITHing Spirit | |
| marcus@vspirit.ch | |
| M: +41 79 20 75 111 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.